Renal denervation in treatment-resistant hypertension: The need for restraint and more and better evidence

Expert Review of Cardiovascular Therapy

Volumn 11, Issue 6, 2013, Pages 739-749

  Persu, Alexandre ^a,b   Renkin, Jean ^a,b   Asayama, Kei ^c   O'Brien, Eoin ^d   Staessen, Jan A ^c,e  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

renal denervation; renal sympathetic nerve ablation; resistant hypertension; sympathetic nervous system

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; EXERCISE; GLUCOSE METABOLISM; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE MASS; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DENERVATION; KIDNEY FUNCTION; KIDNEY NERVE; QUALITY OF LIFE; RESISTANT HYPERTENSION; REVIEW; RISK ASSESSMENT; SLEEP DISORDERED BREATHING; TREATMENT RESISTANT HYPERTENSION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CATHETER ABLATION; COOPERATIVE BEHAVIOR; DRUG RESISTANCE; HUMANS; HYPERTENSION; KIDNEY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SYMPATHECTOMY;

EID: 84878823890     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.13.52     Document Type: Review

References (52)

1. Staessen JA, Kuznetsova T, Stolarz K. Hypertension prevalence and stroke mortality across populations. JAMA 289(18), 2420-2422 (2003).
2. Calhoun DA, Jones D, Textor S et al.; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117(25), e510-e526 (2008).
3. DiBona GF, Kopp UC. Neural control of renal function. Physiol. Rev. 77(1), 75-197 (1997).
4. Gu YM, Asayama K, Liu YP, Staessen JA. Renal denervation: time to open Pandora's box. Swiss Med. Wkly. 142, w13638 (2012).
5. Tsioufis C, Kordalis A, Flessas D et al. Pathophysiology of resistant hypertension: role of the sympathetic nervous system. Int. J. Hypertens. 2011, 642416 (2011).
6. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension 54(4), 690-697 (2009).
7. Pedrosa RP, Drager LF, Gonzaga CC et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension 58(5), 811-817 (2011).
8. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J. Am. Med. Assoc. 152(16), 1501-1504 (1953).
9. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympatheticnerve ablation for uncontrolled hypertension. N. Engl. J. Med. 361(9), 932-934 (2009).
10. Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 54(6), 1195-1201 (2009).
11. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373(9671), 1275-1281 (2009).
12. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376, 1903-1909 (2010).
13. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension. Durability of blood pressure reduction out to 24 months. Hypertension 57, 911-917 (2011).
14. Persu A, Renkin J, Thijs L, Staessen JA. Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension 60(3), 596-606 (2012).
15. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J. Am. Soc. Hypertens. 2(6), 462-468 (2008).
16. de la Sierra A, Segura J, Banegas JR et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 57, 889-890 (2011).
17. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am. J. Hypertens. 19(11), 1190-1196 (2006).
18. Cook S, Goy JJ, Togni M. Optical coherence tomography findings in renal denervation. Eur. Heart J. 33(23), 2992 (2012).
19. Geisler BP, Egan BM, Cohen JT et al. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J. Am. Coll. Cardiol. 60(14), 1271-1277 (2012).
20. Dorenkamp M, Bonaventura K, Leber AW et al. Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension. Eur. Heart J. 34(6), 451-461 (2013).
21. Mahfoud F, Schlaich M, Kindermann I et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 123(18), 1940-1946 (2011).
22. Brandt MC, Mahfoud F, Reda S et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J. Am. Coll. Cardiol. 59(10), 901-909 (2012).
23. Ukena C, Mahfoud F, Kindermann I et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J. Am. Coll. Cardiol. 58(11), 1176-1182 (2011).
24. Zuern CS, Rizas KD, Eick C et al. Effects of renal sympathetic denervation on 24-hour blood pressure variability. Front. Physiol. 3, 134 (2012).
25. Pokushalov E, Romanov A, Corbucci G et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J. Am. Coll. Cardiol. 60(13), 1163-1170 (2012).
26. Mahfoud F, Cremers B, Janker J et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 60(2), 419-424 (2012).
27. Hering D, Mahfoud F, Walton AS et al. Renal denervation in moderate to severe CKD. J. Am. Soc. Nephrol. 23(7), 1250-1257 (2012).
28. Witkowski A, Prejbisz A, Florczak E et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 58(4), 559-565 (2011).
29. Ukena C, Mahfoud F, Spies A et al. Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. Int. J. Cardiol. doi:10.1016/J.ijcard.2012.07.027 (2012) (Epub ahead of print).
30. Himmel F, Weil J, Reppel M et al. Improved heart rate dynamics in patients undergoing percutaneous renal denervation. J. Clin. Hypertens. (Greenwich) 14(9), 654-655 (2012).
31. Brandt MC, Reda S, Mahfoud F, Lenski M, Böhm M, Hoppe UC. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J. Am. Coll. Cardiol. 60(19), 1956-1965 (2012).
32. Lambert GW, Hering D, Esler MD et al. Health-related quality of life after renal denervation in patients with treatmentresistant hypertension. Hypertension 60(6), 1479-1484 (2012).
33. Davies JE, Manisty CH, Petraco R et al. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACHPilot study. Int. J. Cardiol. 162(3), 189-192 (2013).
34. Brinkmann J, Heusser K, Schmidt BM et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension 60(6), 1485-1490 (2012).
35. Ziegler AK, Franke J, Bertog SC. Renal denervation in a patient with prior renal artery stenting. Catheter. Cardiovasc. Interv. 81(2), 342-345 (2013).
36. Hering D, Walton A, Krum H, Lambert GW, Esler MD, Schlaich MP. Renal nerve ablation reduces blood pressure in a patient with renovascular hypertension resistant to drug and revascularisation therapies. Int. J. Cardiol. 159(2), e35-e36 (2012).
37. Himmel F, Bode F, Mortensen K et al. Successful single-sided renal denervation approach in a patient with stenosis of an accessory renal artery. J. Clin. Hypertens. (Greenwich) 14(3), 187-188 (2012).
38. Di Daniele N, De Francesco M, Violo L, Spinelli A, Simonetti G. Renal sympathetic nerve ablation for the treatment of difficult-to-control or refractory hypertension in a haemodialysis patient. Nephrol. Dial. Transplant. 27(4), 1689-1690 (2012).
39. Václavík J, Táborský M, Richter D. Unilateral catheter-based renal sympathetic denervation in resistant arterial hypertension shows no blood pressure-lowering effect. Clin. Exp. Hypertens. 35(3), 192-194 (2013).
40. Vonend O, Antoch G, Rump LC, Blondin D. Secondary rise in blood pressure after renal denervation. Lancet 380(9843), 778 (2012).
41. Kaltenbach B, Id D, Franke JC et al. Renal artery stenosis after renal sympathetic denervation. J. Am. Coll. Cardiol. 60(25), 2694-2695 (2012).
42. Schlaich MP, Straznicky N, Grima M et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J. Hypertens. 29(5), 991-996 (2011).
43. Ukena C, Bauer A, Mahfoud F et al. Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin. Res. Cardiol. 101(1), 63-67 (2012).
44. Shetty SV, Roberts TJ, Schlaich MP. Percutaneous transluminal renal denervation: a potential treatment option for polycystic kidney disease-related pain? Int. J. Cardiol. 162(3), e58-e59 (2013).
45. Rocha-Singh KJ. Renal artery denervation: a brave new frontier. Endovasc. Today 11, 45-52 (2012).
46. Kandzari DE, Bhatt DL, Sobotka PA et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the Symplicity HTN-3 Trial. Clin. Cardiol. 35(9), 528-535 (2012).
47. Bakris GL. Hypertension in 2011: new insights-from risk factors to treatment implications. Nat. Rev. Cardiol. 9(2), 75-77 (2012).
48. Václavík J, Sedlák R, Plachy M et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 57(6), 1069-1075 (2011).
49. Savard S, Frank M, Bobrie G, Plouin PF, Sapoval M, Azizi M. Eligibility for renal denervation in patients with resistant hypertension: when enthusiasm meets reality in real-life patients. J. Am. Coll. Cardiol. 60(23), 2422-2424 (2012).
50. Mahfoud F, Vonend O, Bruck H et al. Interventionelle renale Sympathikusdenervation zur Behandlung der therapieresistenten Hypertonie-Expert consensus statement on interventional renal sympathetic denervation for hypertension treatment. Dtsch. Med. Wochenschr. 136, 2418-2224 (2011).
51. Schmieder RE, Redon J, Grassi G et al. ESH position paper: renal denervation-an interventional therapy of resistant hypertension. J. Hypertens. 30(5), 837-841 (2012).
52. Pathak A, Girerd X, Azizi M et al.; Société Française d'Hypertension Artérielle; Société Française de Cardiologie; Groupe Athérome Coronaire et Interventionnel; Société Française de Radiologie. Expert consensus: renal denervation for the treatment of hypertension. Diagn. Interv. Imaging 93(5), 386-394 (2012).